

Behnam Sadeghi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6568753/publications.pdf>

Version: 2024-02-01

35
papers

1,084
citations

623188

14
h-index

414034

32
g-index

35
all docs

35
docs citations

35
times ranked

1851
citing authors

#	ARTICLE	IF	CITATIONS
1	Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, 839844.	2.2	44
2	Decrease of Tumor-infiltrating Regulatory T Cells using Pentoxifylline: An Ex Vivo Analysis in Triple-negative Breast Cancer Mouse Model. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2022, 21, 167-177.	0.3	3
3	Decidual stromal cell therapy for generalized lymphadenopathy as a special clinical manifestation of COVID-19 infection: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	2
4	Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care. <i>International Journal of Hematology</i> , 2021, 113, 712-722.	0.7	1
5	Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidual stromal cells. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10554-10564.	1.6	20
6	Treatment of radiculomyelopathy in two patients with placenta-derived decidual stromal cells. <i>International Journal of Hematology</i> , 2020, 111, 591-594.	0.7	4
7	The kidney injury caused by the onset of acute graft-versus-host disease is associated with down-regulation of β -Klotho. <i>International Immunopharmacology</i> , 2020, 78, 106042.	1.7	5
8	Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidual Stromal Cells for Acute Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2020, 11, 567210.	2.2	11
9	Effects of 8-hydroxyquinoline-coated graphene oxide on cell death and apoptosis in MCF-7 and MCF-10 breast cell lines. <i>Iranian Journal of Basic Medical Sciences</i> , 2020, 23, 871-878.	1.0	8
10	Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidual Stromal Cells for Severe Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1965-1969.	2.0	14
11	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age \geq 69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1975-1983.	2.0	61
12	Morphological Changes Induced By Extremely Low-Frequency Electric Fields. <i>Bioelectromagnetics</i> , 2019, 40, 375-390.	0.9	3
13	The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor. <i>Transplantation</i> , 2019, 103, 1247-1252.	0.5	3
14	Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidual Stromal Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2685.	2.2	20
15	Placenta-Derived Decidual Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease. <i>Stem Cells Translational Medicine</i> , 2018, 7, 325-331.	1.6	75
16	Placenta-Derived Decidual Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation. <i>Acta Haematologica</i> , 2018, 139, 106-114.	0.7	28
17	Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2018, 107, 478-485.	0.7	11
18	Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease. <i>Pediatric Transplantation</i> , 2017, 21, e12990.	0.5	4

#	ARTICLE	IF	CITATIONS
19	Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of <scp>EBMT</scp>. <i>British Journal of Haematology</i> , 2017, 176, 431-439.	1.2	26
20	Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis. <i>Frontiers in Immunology</i> , 2017, 8, 795.	2.2	37
21	Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice. <i>International Immunopharmacology</i> , 2016, 40, 41-49.	1.7	13
22	Placenta-Derived Decidual Stromal Cells for Graft-Versus-Host Disease, Hemorrhaging, and Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S149.	2.0	6
23	Immunogenicity of Decidual Stromal Cells in an Epidermolysis Bullosa Patient and in Allogeneic Hematopoietic Stem Cell Transplantation Patients. <i>Stem Cells and Development</i> , 2015, 24, 1471-1482.	1.1	20
24	Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua. <i>Stem Cells and Development</i> , 2015, 24, 2269-2279.	1.1	104
25	Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity in vitro and in vivo. <i>Cytotherapy</i> , 2015, 17, 1732-1745.	0.3	17
26	Decreased Risk of Acute Graft-versus-Host Disease Using Reduced Intensity Conditioning Compared to Myeloablative Conditioning is Independent of Donor-Recipient T-cell Chimerism. <i>Journal of Transplantation Technologies & Research</i> , 2014, 04, .	0.1	1
27	The Role of Programmed Cell Death Ligand-1 (PD-L1/CD274) in the Development of Graft versus Host Disease. <i>PLoS ONE</i> , 2013, 8, e60367.	1.1	14
28	Is Graft-versus-Leukemia More Effective Using Reduced-Intensity Conditioning Compared with Myeloablative Conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1615-1617.	2.0	2
29	Busulphan-Cyclophosphamide Cause Endothelial Injury, Remodeling of Resistance Arteries and Enhanced Expression of Endothelial Nitric Oxide Synthase. <i>PLoS ONE</i> , 2012, 7, e30897.	1.1	29
30	Inhibition of proteasome deubiquitinating activity as a new cancer therapy. <i>Nature Medicine</i> , 2011, 17, 1636-1640.	15.2	431
31	Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen. <i>International Journal of Clinical and Experimental Pathology</i> , 2011, 4, 596-605.	0.5	8
32	Expansion and Activation Kinetics of Immune Cells during Early Phase of GVHD in Mouse Model Based on Chemotherapy Conditioning. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-13.	3.3	16
33	A New Mice Model of Graft Versus Host Disease Based on Chemotherapy Conditioning.. <i>Blood</i> , 2007, 110, 4880-4880.	0.6	0
34	Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease.. <i>Clinical Biochemistry</i> , 2001, 34, 309-315.	0.8	40
35	7 Mesenchymal stem cells for graft-versus-host disease in experimental animal models. , 0, , .		3